I-Mab Announces Upcoming Participation at September Conferences

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

News Market Reaction – IMAB

The recorded move for IMAB in the trading session of this news was -7.73%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

09/05/2023 - 08:00 AM EDT

ROCKVILLE, Md. and SHANGHAI, Sept. 5, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics for oncology, today announced its participation in the following conferences in September 2023. Details of the conferences and management presentation are as follows:

H.C. Wainwright 25^th Annual Global Investment Conference (Hybrid)

Presentation: Monday, September 11^th at 11:30 a.m. E.S.T

Presenter: Mr. Raj Kannan, CEO

One-on-one and small group meetings: Sept 11-13, 2023

Management participants: Mr. Raj Kannan, CEO; Dr. John Hayslip, CMO; Dr. Andrew Zhu, President and Head of R&D; and Mr. Tyler Ehler, Senior Director, Investor Relations

For more information, please contact your H.C. Wainwright representative.

2023 Cantor Global Healthcare Conference (In Person)

Presentation: Thursday, September 28^th at 2:25 p.m. E.S.T.

Presenter: Mr. Raj Kannan, CEO; and Dr. John Hayslip, CMO

One-on-one and small group meetings: Sept 26-28, 2023

Management participants: Mr. Raj Kannan, CEO; Dr. John Hayslip, CMO; and Mr. Tyler Ehler, Senior Director, Investor Relations

For more information, please contact your Cantor representative.

About I-Mab

I-Mab (Nasdaq: IMAB) is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics for oncology. I-Mab's innovative pipeline is driven by internal R&D's Fast-to-Proof-of-Concept, Fast-to-Market development strategies, and through global partnerships. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn, Twitter, and WeChat.

I-Mab Contacts